Technical Analysis for AGLE - Aeglea BioTherapeutics, Inc.

Grade Last Price % Change Price Change
grade B 8.92 -0.45% -0.04
AGLE closed down 0.45 percent on Friday, January 18, 2019, on 84 percent of normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Up
See historical AGLE trend table...

Date Alert Name Type % Chg
Jan 18 Slingshot Bullish Bullish Swing Setup 0.00%
Jan 18 Wide Bands Range Expansion 0.00%
Jan 18 Overbought Stochastic Strength 0.00%
Jan 17 Narrow Range Bar Range Contraction -0.45%
Jan 17 NR7 Range Contraction -0.45%
Jan 17 Wide Bands Range Expansion -0.45%
Jan 17 Overbought Stochastic Strength -0.45%
Jan 16 Wide Bands Range Expansion -1.87%
Jan 16 Overbought Stochastic Strength -1.87%
Jan 15 180 Bullish Setup Bullish Swing Setup 2.65%

Older signals for AGLE ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Aeglea Biotherapeutics, Inc., a biopharmaceutical company, engages in developing engineered human enzymes for the treatment of inborn errors of metabolism and cancer. It develops AERase/AEB1102, an amino acid for the degradation of arginine in the circulation, as well as for the treatment of hyperargininemia and cancer; and AECase/AEB3103, an engineered and PEGylated human cysteine/cystine degrading enzyme that increases oxidative stress through glutathione depletion for treatment of hematologic and solid malignancies. The company also engages in developing AEMase/AEB2109, an engineered human enzyme that degrades methionine for the treatment of solid tumors; and AEB4104, an engineered human enzyme that degrades homocysteine in the circulation for the treatment of inborn error of metabolism homocystinuria. It has a strategic partnership with KBI Biopharma. Aeglea Biotherapeutics, Inc. was formerly known as Aeglea BioTherapeutics Holdings, LLC. The company was founded in 2013 and is based in Austin, Texas.
Is AGLE a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 12.0
52 Week Low 5.12
Average Volume 117,720
200-Day Moving Average 9.1732
50-Day Moving Average 8.1196
20-Day Moving Average 8.115
10-Day Moving Average 8.647
Average True Range 0.5201
ADX 17.98
+DI 22.356
-DI 14.4124
Chandelier Exit (Long, 3 ATRs ) 7.6097
Chandelier Exit (Short, 3 ATRs ) 7.8703
Upper Bollinger Band 9.4612
Lower Bollinger Band 6.7688
Percent B (%b) 0.8
BandWidth 33.178065
MACD Line 0.2662
MACD Signal Line 0.1502
MACD Histogram 0.116
Fundamentals Value
Market Cap 146.75 Million
Num Shares 16.5 Million
EPS -1.81
Price-to-Earnings (P/E) Ratio -4.93
Price-to-Sales 15.71
Price-to-Book 1.22
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 9.50
Resistance 3 (R3) 9.50 9.30 9.40
Resistance 2 (R2) 9.30 9.15 9.30 9.37
Resistance 1 (R1) 9.11 9.06 9.01 9.11 9.34
Pivot Point 8.92 8.92 8.87 8.92 8.92
Support 1 (S1) 8.73 8.77 8.63 8.73 8.50
Support 2 (S2) 8.53 8.68 8.53 8.47
Support 3 (S3) 8.34 8.53 8.44
Support 4 (S4) 8.34